Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lada Leyens

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Public Health Genomics|May 31, 2016
Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization MethodsLada Leyens, Angela Brand
Exploratory Research in Clinical and Social Pharmacy|April 10, 2025
Employing bibliometrics and natural language processing (NLP) to analyse real-world applications of adverse drug reactionViola Savy Dsouza, Lada Leyens, Angela Brand
Trials|September 30, 2022
The COVID-19 pandemic as a catalyst for innovation: a regulatory framework to assess fit-for-purpose innovative approaches in clinical researchLada Leyens, Tracy Simkins, Nafsika Kronidou Horst
Genetic Epidemiology|November 23, 2016
Use of big data for drug development and for public and personal health and careLada Leyens, Matthias Reumann, Nuria Malats, et al.
Public Health Genomics|November 14, 2015
Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical ResearchRachel Syme, Bruce Carleton, Lada Leyens, et al.
Public Health Genomics|August 29, 2015
Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized MedicineLada Leyens, Étienne Richer, Øyvind Melien, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|May 15, 2024
Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaborationLada Leyens, John Batchelor, Erwin De Beuckelaer, et al.
Research in Social & Administrative Pharmacy : RSAP|February 17, 2025
Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patientsViola Savy Dsouza, Lada Leyens, Jestina Rachel Kurian, et al.
Advances in Experimental Medicine and Biology|December 8, 2017
Personalized Medicine: What's in it for Rare Diseases?Sebastian Schee Genannt Halfmann, Laura Mählmann, Lada Leyens, et al.
Digital Biomarkers|January 15, 2024
Why Language Matters in Digital Endpoint Development: Harmonized Terminology as a Key Prerequisite for Evidence GenerationLada Leyens, Carrie A Northcott, Lesley Maloney, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Public Health Genomics|May 31, 2016
Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization MethodsLada Leyens, Angela Brand
Exploratory Research in Clinical and Social Pharmacy|April 10, 2025
Employing bibliometrics and natural language processing (NLP) to analyse real-world applications of adverse drug reactionViola Savy Dsouza, Lada Leyens, Angela Brand
Trials|September 30, 2022
The COVID-19 pandemic as a catalyst for innovation: a regulatory framework to assess fit-for-purpose innovative approaches in clinical researchLada Leyens, Tracy Simkins, Nafsika Kronidou Horst
Genetic Epidemiology|November 23, 2016
Use of big data for drug development and for public and personal health and careLada Leyens, Matthias Reumann, Nuria Malats, et al.
Public Health Genomics|November 14, 2015
Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical ResearchRachel Syme, Bruce Carleton, Lada Leyens, et al.
Public Health Genomics|August 29, 2015
Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized MedicineLada Leyens, Étienne Richer, Øyvind Melien, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|May 15, 2024
Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaborationLada Leyens, John Batchelor, Erwin De Beuckelaer, et al.
Research in Social & Administrative Pharmacy : RSAP|February 17, 2025
Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patientsViola Savy Dsouza, Lada Leyens, Jestina Rachel Kurian, et al.
Advances in Experimental Medicine and Biology|December 8, 2017
Personalized Medicine: What's in it for Rare Diseases?Sebastian Schee Genannt Halfmann, Laura Mählmann, Lada Leyens, et al.
Digital Biomarkers|January 15, 2024
Why Language Matters in Digital Endpoint Development: Harmonized Terminology as a Key Prerequisite for Evidence GenerationLada Leyens, Carrie A Northcott, Lesley Maloney, et al.
Pageof 3